Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more
Newron Pharmaceuticals S.p.A. (0QOI) - Total Liabilities
Latest total liabilities as of June 2025: £59.81 Million GBP
Based on the latest financial reports, Newron Pharmaceuticals S.p.A. (0QOI) has total liabilities worth £59.81 Million GBP as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Newron Pharmaceuticals S.p.A. - Total Liabilities Trend (2005–2024)
This chart illustrates how Newron Pharmaceuticals S.p.A.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Newron Pharmaceuticals S.p.A. Competitors by Total Liabilities
The table below lists competitors of Newron Pharmaceuticals S.p.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
RITES Limited
NSE:RITES
|
India | ₹33.18 Billion |
|
Guangdong Delian Group Co Ltd
SHE:002666
|
China | CN¥1.67 Billion |
|
Shenzhen Fluence Technology PLC
SHE:300647
|
China | CN¥1.67 Billion |
|
Tianjin Tianbao Infrastructure Co Ltd
SHE:000965
|
China | CN¥8.82 Billion |
|
Da-Li Development Co Ltd
TW:6177
|
Taiwan | NT$33.80 Billion |
|
Siam Global House Public Company Limited
BK:GLOBAL
|
Thailand | ฿14.40 Billion |
|
Calbee Inc
PINK:CLBEY
|
USA | $111.67 Billion |
|
BK Technologies Inc
NYSE MKT:BKTI
|
USA | $25.91 Million |
Liability Composition Analysis (2005–2024)
This chart breaks down Newron Pharmaceuticals S.p.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 37.81 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.97 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Newron Pharmaceuticals S.p.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Newron Pharmaceuticals S.p.A. (2005–2024)
The table below shows the annual total liabilities of Newron Pharmaceuticals S.p.A. from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | £62.45 Million | +11.97% |
| 2023-12-31 | £55.77 Million | +8.88% |
| 2022-12-31 | £51.23 Million | +8.12% |
| 2021-12-31 | £47.38 Million | +39.55% |
| 2020-12-31 | £33.95 Million | +44.54% |
| 2019-12-31 | £23.49 Million | +354.97% |
| 2018-12-31 | £5.16 Million | -2.64% |
| 2017-12-31 | £5.30 Million | -22.52% |
| 2016-12-31 | £6.84 Million | -5.83% |
| 2015-12-31 | £7.27 Million | -6.98% |
| 2014-12-31 | £7.81 Million | -25.79% |
| 2013-12-31 | £10.53 Million | -38.21% |
| 2012-12-31 | £17.04 Million | +144.08% |
| 2011-12-31 | £6.98 Million | +0.58% |
| 2010-12-31 | £6.94 Million | -44.00% |
| 2009-12-31 | £12.39 Million | -15.85% |
| 2008-12-31 | £14.73 Million | +13.58% |
| 2007-12-31 | £12.97 Million | -29.13% |
| 2006-12-31 | £18.30 Million | +182.52% |
| 2005-12-31 | £6.48 Million | -- |